Blocking of MIF activity either by antibodies or stable RNA interference reduced tumor growth in animal models of colorectal cancer [29], prostate cancer [30], ovarian cancer [20], neuroblastoma [31], pancreatic cancer [10], breast cancer [9], melanoma [22, 32] and lung cancer [28]. Here, MIF is linked to prostate carcinoma.